Corcept Therapeutics Stock Drops 50% After FDA Rejection
The company received bad news from a top regulator on the last day of 2025.
Corcept Therapeutics, a biotech company from California, received bad news from the FDA. The FDA did not approve their drug relacorilant, which treats Cushing's syndrome, a rare hormonal disorder. Even though the drug passed its main test, the FDA said there was not enough proof that it works well.
The company's stock price fell 50% on that day. The FDA wants more evidence before they can approve the drug. Corcept plans to meet with FDA officials to find new ways forward.
The company may need to do more clinical trials.
This article has been summarized and translated using AI to help you practice reading and comprehension. While we strive for accuracy, some nuances may be lost in translation.